探索已发表和新型治疗前CT与PET影像组学特征对接受立体定向放疗的早期非小细胞肺癌患者进展风险的分层
本研究在408例连续接受SBRT的早期NSCLC患者中探索已发表及新型治疗前CT和PET影像组学特征,采用自助法Cox回归和逐步多因素分析筛选PFS预测因子。包含肿瘤直径和SUVmax的重新拟合模型表现最佳,c-index为0.78(log-rank P<0.0001),成功对SBRT后PFS进行分层。
要点
- 肿瘤直径和SUVmax是已发表研究中最常报告的与进展/生存相关的特征(分别在6/20和10/20项研究中)。
- 包含肿瘤直径和SUVmax的重新拟合模型表现最佳,c-index为0.78,log-rank P<0.0001。
- 由两个最佳额外特征(CT毛刺征1和SUV熵)构建的模型c-index为0.75,log-rank P<0.0001。
核心结论
- 使用两个最常发表的模式特征——肿瘤直径和SUVmax——重新拟合的治疗前模型成功对接受SBRT的早期NSCLC患者按PFS进行分层。
研究设计与样本
- 在408例连续治疗的早期NSCLC患者中探索已发表和新型治疗前CT与PET影像组学特征,患者均在SBRT前3个月内接受CT和PET检查(训练集/留出验证集:n=286/122)。
主要发现
- 肿瘤直径和SUVmax是已发表研究中最常报告的与进展/生存相关的特征,分别在6/20和10/20项纳入研究中报告。
- 这两个特征及15个额外特征中的12个(CT:6个;PET:6个)为候选PFS预测因子。
- 包含肿瘤直径和SUVmax的重新拟合模型表现最佳,c-index为0.78,log-rank P<0.0001。
- 由两个最佳额外特征(CT毛刺征1和SUV熵)构建的模型c-index为0.75,log-rank P<0.0001。
关键数值与推荐
- 单变量预测因子经Bonferroni校正后要求p≤0.002。
- 仅保留非强相关预测因子(|Rs|<0.70)进入前向逐步多因素分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Disease progression after definitive stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) occurs in 20-40% of patients. Here, we explored published and novel pre-treatment CT and PET radiomics features to identify patients at risk of progression. MATERIALS/METHODS: Published CT and PET features were identified and explored along with 15 other CT and PET features in 408 consecutively treated early-stage NSCLC patients having CT and PET < 3 months pre-SBRT (training/set-aside validation subsets: n = 286/122). Features were associated with progression-free survival (PFS) using bootstrapped Cox regression (Bonferroni-corrected univariate predictor: p ≤ 0.002) and only non-strongly correlated predictors were retained (|Rs|<0.70) in forward-stepwise multivariate analysis. RESULTS: Tumor diameter and SUVmax were the two most frequently reported features associated with progression/survival (in 6/20 and 10/20 identified studies). These two features and 12 of the 15 additional features (CT: 6; PET: 6) were candidate PFS predictors. A re-fitted model including diameter and SUVmax presented with the best performance (c-index: 0.78; log-rank p-value < 0.0001). A model built with the two best additional features (CTspiculation1 and SUVentropy) had a c-index of 0.75 (log-rank p-value < 0.0001). CONCLUSIONS: A re-fitted pre-treatment model using the two most frequently published features - tumor diameter and SUVmax - successfully stratified early-stage NSCLC patients by PFS after receiving SBRT.
引用
- Thor M, Fitzgerald K, Apte A, et al. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation. Radiother Oncol. 2023. PMID: 37926331. doi:10.1016/j.radonc.2023.109983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。